Author: NSV

Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million

Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million

Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive

Read More
Phase Four unveils game changing engine for LEO Constellations

Phase Four unveils game changing engine for LEO Constellations

Leveraging its new Block 2 architecture, Phase Four announces Max-V, a revolutionary plasma propulsion system available in 2023. Phase Four, the creator of the radio-frequency thruster for satellite propulsion, has announced that it will expand its Maxwell turn-key plasma propulsion line and offer satellite manufacturers an industry-first high performance engine

Read More
Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958

Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958

Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a

Read More
Parker Aerospace and DUST Identity launch Lockheed Martin F-35 into digital space

Parker Aerospace and DUST Identity launch Lockheed Martin F-35 into digital space

Weaving together digital engineering and technology, Parker Aerospace today announced collaboration with Lockheed Martin and DUST Identity. The alliance implements DUST technology to connect Parker Aerospace products with Lockheed Martin aircraft to track parts from build to delivery and maintenance. The collaboration optimizes Parker Aerospace product traceability and supply chain

Read More
Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735

Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a multi-asset, clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735,

Read More
Cambridge Epigenetix names Peter Fromen as Chief Executive Officer

Cambridge Epigenetix names Peter Fromen as Chief Executive Officer

Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, has announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022. Gail Marcus who has been acting Chief Executive Officer since 2020 will continue as Chair of the Board. Professor

Read More
Vascular Therapies completes $25 million private financing

Vascular Therapies completes $25 million private financing

Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, has announced the closing of a $25 million private financing. The financing comprised of existing and new investors, including a Fortune 100 global healthcare company. Vascular Therapies plans to use the proceeds

Read More
Paragraf raises $60 million in Series B financing

Paragraf raises $60 million in Series B financing

Paragraf has announced the close of its $60m Series B round. The round is being led by New Science Ventures, a US deep tech investor, investing in novel scientific approaches in the Life Sciences and Information Technology sectors, which is very well aligned with Paragraf’s growth aspirations.  The round included

Read More
NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease

NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease

NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, has announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD. IFALD is a multifactorial condition

Read More
NorthSea Therapeutics completes $80 million Series C fundraising to advance clinical programs in metabolic disorders

NorthSea Therapeutics completes $80 million Series C fundraising to advance clinical programs in metabolic disorders

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced the close of a USD 80 million Series C financing round. The financing round was co-led by Ysios Capital and Forbion Growth and joined by

Read More
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity

Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity

NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, has announced the presentation of new interim data from the Phase 2b ICONA trial during The Liver Meeting Digital Experience 2021 (TLMdX) of the American Association for the Study

Read More
Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform

Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform

Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, has announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing

Read More